SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are recommended as second-line therapy after metformin in uncomplicated type 2 diabetes, whereas they are recommended as first-line treatment in patients with heart failure or other cardiorenal comorbidities.